NCT06017544View on ClinicalTrials.gov

GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Patients with Type 2 Diabetes.

CompletedOBSERVATIONAL
Enrollment

257

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

June 1, 2024

Study Completion Date

December 1, 2024

Conditions
Diabetes Mellitus, Type 2Myocardial Infarction
Interventions
PROCEDURE

PCI

The T2DM affected by AMI will be referred for receiving PCI.

Trial Locations (1)

80138

Celestino Sardu, Naples

All Listed Sponsors
lead

University of Campania Luigi Vanvitelli

OTHER

NCT06017544 - GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Patients with Type 2 Diabetes. | Biotech Hunter | Biotech Hunter